Clinical utility of FDG PET

Journal of Medical Investigation

Volumn 51, Issue 1-2, 2004, Pages 14-19

  Otsuka, Hideki ^a,b   Graham, Michael ^a   Kubo, Akiko ^b   Nishitani, Hiromu ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

FDG PET; Head and neck cancer; Restaging; Staging; Therapy monitoring

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TRACER; DIAGNOSTIC AGENT;

ACCURACY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HUMAN; IMAGING; IMAGING SYSTEM; LUNG CANCER; NORMAL DISTRIBUTION; POSITRON EMISSION TOMOGRAPHY; REVIEW; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HEAD AND NECK TUMOR; LUNG TUMOR; MALE; METHODOLOGY; NEOPLASM; SCINTISCANNING; STATISTICAL ANALYSIS; STATISTICS;

DATA INTERPRETATION, STATISTICAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1842830281     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.51.14     Document Type: Review

References (24)

1. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 44 (4): 540-8, 2003
2. 18F-FDG PET in patients with cervical cancer. J Nucl Med 44 (3): 347-52, 2003
3. Fogarty GB, Peters LJ, Stewart J, Scott C, Rischin D, Hicks RJ: The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck 25 (2):138-45, 2003
4. Brun E, Kjellen E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, Perfekt R, Wennerberg J, Strand SE: FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24 (2): 127-35, 2002
5. Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS: Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 23 (12): 1056-60, 2001
6. 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 44 (5): 690-9, 2003
7. Brenner W, Bohuslavizki KH, Eary JF: PET imaging of osteosarcoma. J Nucl Med 44 (6): 930-42, 2003
8. Kostakoglu L, Agress H, Goldsmith S: Clinical Role of FDG PET in Evaluation of Cancer Patients. RadioGraphics 23: 315-340, 2003
9. Shreve PD, Huy Bui CD: Normal Variants in FDG PET Imaging. Principles and Practice of Positron Emission Tomography. LIPPINCOTT WILLIAMS & WILKINS, Philladelphia, 2002, pp.111-124
10. Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, Chisin R, Larson SM: FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 28 (2): 155-64, 2001
11. Hollenbeak CS, Lowe VJ, Stack BC Jr: The cost-effectiveness of fluorodeoxyglucose18-F positron emission tomography in the NO neck. Cancer. 92 (9): 2341-8, 2001
12. Davis JP, Maisey NM, Chevreton EB: Positron emission tomography: a useful imaging technique for otolaryngology, head and neck surgery? J Laryngol Otol 112 (2): 125-7, 1998
13. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25 (9): 1255-60, 1998
14. Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W: Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 125 (12):1322-8, 1999
15. 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol 19 (7): 1189-96, 1998
16. Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, Wahl RL: Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18] fluoro-D-glucose PET and MR imaging diagnoses. Radiology 200 (1): 135-41, 1996
17. Wong WL, Chevretton EB, McGurk M, Hussain K, Davis J, Beaney R, Baddeley H, Tierney P, Maisey M: A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 22 (3): 209-14, 1997
18. Lowe VJ, Dunphy FR, Varvares M, Kim H, Wittry M, Dunphy CH, Dunleavy T, McDonough E, Minster J, Fletcher JW, Boyd JH: Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18] fluorodeoxyglucose positron emission tomography. Head Neck 19 (8): 666-74, 1997
19. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 21: 285 (7): 914-24, 2001
20. Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, Weder W: Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 202 (2): 441-6,1997
21. 18F-FDG PET in Characterizing Adrenal Lesions Detected on CT or MRI. J Nucl Med 42: 1795-1799, 2001
22. Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, Matthews JP, Ball DL: (18) F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 42 (11): 1596-604, 2001
23. Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, Ball DL: The utility of (18) F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 42 (11):1605-13, 2001
24. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M J: Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. Clin Oncol 21 (14):2651-7, 2003